At the same time, MAP4K1, G6PD, CDK18, SOCS1, ETS2, and AKR1B1 showed opposite trends (Supplementary Figures S2C,S2F), suggesting that KDM5B and SMURF2 might be protective factors for AML patients. This evidence concerns the gene MAP4K1 and acute myeloid leukemia.